Skip to main content

Table 3 Results of the different cost-effectiveness analyses

From: Long-term efficacy and cost-effectiveness of blended cognitive behavior therapy for high fear of recurrence in breast, prostate and colorectal Cancer survivors: follow-up of the SWORD randomized controlled trial

  Unadjusted Adjusted QLQ-C30
bCBT CAU bCBT CAU bCBT CAU
Costs Mean 6001 6165 6001 6165 6001 6165
95% CI 4552 to 7664 4657 to 7850 4552 to 7664 4657 to 7850 4552 to 7664 4657 to 7850
Incremental costs Mean −164 −164 −164
95% CI −2018 to 2502 −2018 to 2502 −2018 to 2502
QALYs Mean 1.027 0.913 0.984 0.957 1.107 1.074
  95% CI 0.966 to 1.083 0.839 to 0.980 0.941 to 1.028 0.912 to 1.001 1.074 to 1.135 1.046 to 1.100
Incremental QALYs Mean 0.114 0.028 0.033
95% CI 0.026 to 0.206* −0.031 to 0.090 −0.012 to 0.072
ICER   €-1081 / QALY €2049 / QALY €-6189 / QALY
INMB at WTP of 0 Mean €164 €-57 €164
95% CI €-2018 to €2502 €-2709 to €2370 €-2081 to 2419
INMB at WTP of €20,000 Mean €2403 €498 €807
95% CI €-893 to €5454 €-2514 to €3269 €-1898 to €3249
INMB at WTP of €50,000 Mean €5761 €1331 €1770
95% CI €386 to €11,274* €-3189 to €5773 €-1322 to €5064
  1. NOTE. Unadjusted and adjusted cost-effectiveness analyses used QALYs calculated from EQ-5D utilities, while the QLQ-C30 analysis used QALYs calculated from EORTC QLQ-C30 utilities. Estimates in the adjusted cost-effectiveness analysis were adjusted for baseline EQ-5D utility scores. Confidence intervals were obtained after bootstrapping with 1000 replications
  2. Abbreviations: bCBT blended cognitive behaviour therapy, CAU care as usual, QLQ-C30 European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30, ICER incremental cost-effectiveness ratio, INMB incremental net monetary benefit, WTP willingness to pay, QALY quality adjusted life-year
  3. *Significant difference between the two conditions (p < 0.05)